Delving into the Latest Updates on Icotrokinra Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide, Cyclic Peptide

Synonyms

Icotrokinra, 伊科托金拉, 依可替金拉

+ [14]

Target

IL-23R

Action

inhibitors

Mechanism

IL-23R inhibitors(Interleukin 23 Receptor inhibitors)

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal DiseasesOther Diseases+ [2]

Active Indication

Erythrodermic psoriasisPustular psoriasisPlaque psoriasis+ [6]

Inactive Indication-

Originator Organization

Janssen Biotech, Inc.

Active Organization

Janssen Pharmaceutica NVJanssen Research & Development LLC

Johnson & Johnson

+ [7]

Inactive Organization

Protagonist Therapeutics, Inc.

License Organization

Protagonist Therapeutics, Inc.

Janssen Biotech, Inc.

Drug Highest PhaseApproved

First Approval Date

United States (17 Mar 2026),

Plaque psoriasis

RegulationPriority Review (China)

Login to view timeline

Structure/Sequence

Sequence Code 1311911322

Source: *****

A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults With an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy With Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis

The purpose of this protocol is to evaluate the efficacy (how well it works), safety and tolerability of oral icotrokinra as therapy in adult and adolescent participants with moderately to severely active ulcerative colitis (UC, a chronic disease of the large intestine in which the lining of the colon becomes inflamed and develops tiny open ulcers).

Start Date01 Oct 2025

Sponsor / Collaborator

Janssen Research & Development LLC

100 Clinical Results associated with Icotrokinra Hydrochloride

Login to view more data

100 Translational Medicine associated with Icotrokinra Hydrochloride

Login to view more data

100 Patents (Medical) associated with Icotrokinra Hydrochloride

Login to view more data

35

Literatures (Medical) associated with Icotrokinra Hydrochloride

15 Oct 2026·NEW ENGLAND JOURNAL OF MEDICINE

Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis

Article

Author: Arthur, Edmund ; Zhan, Joyce ; Vetter, Marion L. ; Kannan, Arun K. ; Louis, Edouard ; Limdi, Jimmy ; Loftus, Edward V. ; Marano, Colleen ; Houck, Nicole ; Surace, Lindsey ; Matsuoka, Katsuyoshi ; Siegmund, Britta ; Frustaci, Mary Ellen ; Abreu, Maria T. ; Rydzewska, Grazyna ; Erondu, Ngozi ; Jairath, Vipul ; Chen, Minhu ; Zou, Bin ; Chachu, Karen

BACKGROUND:

Monoclonal antibodies targeting the interleukin-23 pathway are effective in treating inflammatory bowel disease. However, these therapies must be administered intravenously or by subcutaneous injection.

METHODS:

We conducted a phase 2b, double-blind, randomized trial of oral icotrokinra, a peptide that blocks the interleukin-23 receptor, in adults with moderately to severely active ulcerative colitis. Participants were assigned to receive icotrokinra at a once-daily dose of 400 mg, 200 mg, or 100 mg or placebo. The primary end point was clinical response at week 12. Secondary end points included clinical remission, remission of symptoms, and endoscopic improvement at week 12.

RESULTS:

A total of 252 participants underwent randomization: 63 were assigned to the 400-mg group, 62 to the 200-mg group, 64 to the 100-mg group, and 63 to the placebo group. All the doses of icotrokinra were superior to placebo with respect to a clinical response at week 12, which occurred in 63% of the participants in the 400-mg group, 58% in the 200-mg group, and 55% in the 100-mg group, as compared with 27% in the placebo group (P<0.001 for all comparisons with placebo). The percentage of participants with clinical remission at week 12 was also significantly higher in the 400-mg group than in the placebo group (30% vs. 11%, P = 0.006), as were the percentage of participants with symptomatic remission (46% vs. 19%, P<0.001) and the percentage of participants with endoscopic improvement (37% vs. 14%, P = 0.002). Clinical remission at week 12 occurred in 24% of the participants in the 200-mg group (P = 0.054 for the comparison with placebo); in accordance with the fixed-sequence testing procedure to account for multiple comparisons, no further formal testing of secondary end points was conducted. Through week 28, the percentage of participants with adverse events was 60% in the 400-mg group, 66% in the 200-mg group, 66% in the 100-mg group, and 62% in the placebo group. For serious adverse events, the percentages were 2%, 5%, 0%, and 10%, respectively.

CONCLUSIONS:

Among participants with moderately to severely active ulcerative colitis, a clinical response at week 12 was significantly more common with once-daily oral icotrokinra at each of three tested doses than with placebo. (Funded by Johnson & Johnson; ANTHEM-UC ClinicalTrials.gov number, NCT06049017.).

01 Oct 2026·Dermatology and Therapy

Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials

Article

Author: Ofori, Sarah ; Russo, Christopher ; Rubens, Jessica H ; Stein Gold, Linda ; Li, Shu ; Hsu, Ming-Chun ; Cardillo, Tracy ; Soung, Jennifer ; Anaya Velarde, Luis ; Miller-Kassamali, Megan ; Warren, Richard B ; DeKlotz, Cynthia M C ; Hebert, Adelaide A ; Eichenfield, Lawrence F ; Bissonnette, Robert ; Lebwohl, Mark G ; Gooderham, Melinda ; Yang, Ya-Wen

INTRODUCTION:

Icotrokinra, a first-in-class targeted oral peptide, precisely blocks the interleukin (IL)-23 receptor and inhibits IL-23 pathway signaling. In phase 3 studies (ICONIC-LEAD, ICONIC-TOTAL, ICONIC-ADVANCE 1 and 2), icotrokinra provided superior skin clearance versus placebo and deucravacitinib in adults and adolescents with moderate-to-severe psoriasis and psoriasis affecting high-impact sites. This analysis evaluates icotrokinra safety through 1 year using pooled data from these four studies.

METHODS:

Icotrokinra-randomized participants received 200-mg pills once daily, and placebo-randomized participants crossed over to icotrokinra at week 16; participants randomized to deucravacitinib 6 mg (ICONIC-ADVANCE 1 and 2 only) switched to icotrokinra at week 24. Pooled safety data are summarized for the placebo-controlled period (week 0-16, all studies), active-controlled period (week 0-24, ICONIC-ADVANCE 1 and 2), and through week 52 (all studies).

RESULTS:

During the placebo-controlled period across all studies, 568 participants received placebo and 1296 received icotrokinra. From week 0 to 24 in the ICONIC-ADVANCE studies, 632 participants received icotrokinra and 634 received deucravacitinib. Through week 52, 2400 icotrokinra-treated participants contributed 1840 participant-years [PY] of follow-up. Through week 16, in the icotrokinra and placebo groups, respectively, exposure-adjusted incidence rates/100 PY of adverse events (AEs; 232 and 269), serious AEs (5.2 and 6.6), infections (91 and 104), and AEs leading to discontinuation (6.6 and 10.0) were comparable between groups. Through week 24, in the ICONIC-ADVANCE studies, rates/100 PY with icotrokinra versus deucravacitinib were as follows: AEs, 204 vs 265; serious AEs, 6.4 vs 7.2; infections, 81 vs 119; AEs leading to discontinuation, 5.7 vs 6.8. Through week 52, event rates/100 PY in icotrokinra-treated participants were as follows: AEs, 167; serious AEs, 4.6; infections, 76; AEs leading to discontinuation, 3.0.

CONCLUSION:

In this analysis of 2400 icotrokinra-treated participants with psoriasis followed through 1 year, icotrokinra demonstrated favorable safety; event rates through week 16 were similar to placebo and remained consistent through week 52.

CLINICALTRIALS:

GOV: NCT06095115, NCT06095102, NCT06143878, NCT06220604. Infographic available for this article. INFOGRAPHIC.

01 Oct 2026·JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study

Article

Author: Soung, Jennifer ; Bissonnette, Robert ; Prajapati, Vimal H ; Jiang, Jingzhi ; Cafone, Joseph ; González-Cantero, Álvaro ; Li, Shu ; Rich, Phoebe ; Miller-Kassamali, Megan ; Pinter, Andreas ; Lebwohl, Mark G ; Cui, Yong ; Yang, Ya-Wen ; Pink, Andrew E

253

News (Medical) associated with Icotrokinra Hydrochloride

23 Oct 2026

·www.fiercebiotech.com

Gilead to pay $1.3B upfront for PepStar’s oral IL-23 challenger to J&J’s Icotyde

Gilead has struck a deal to acquire PepStar Therapeutics’ oral IL-23 receptor inhibitor program for $1.275 billion, positioning itself as a would-be challenger to Johnson & Johnson’s Icotyde across a range of inflammatory diseases. Injectable IL-23 drugs are big business. Skyrizi racked up nearly $10 billion for AbbVie over the first half of the year, and J&J has talked up Icotyde’s launch without sharing sales data. Skyrizi is typically administered via subcutaneous injection, although initial intravenous infusion doses are required for some indications. Patients take Icotyde orally once daily. Gilead is betting big that there is room for another product. The big biotech is acquiring global rights to PepStar’s IL-23 receptor inhibitor program, including HCXT-2001, from the Shanghai-based company in return for the upfront payment. HCXT-2001 is in phase 1 development. BMO Capital Markets analysts welcomed the deal in a note to investors, calling it “a logical complement to emvistegrast that sets up a potential all-oral combination.” Emvistegrast, Gilead’s inhibitor of the α4β7 pathway, recently impressed in a phase 2 trial. Researchers added an HCXT-2001 study to China’s clinical trial registry in August and uploaded a second study to the database the following month. Both trials are enrolling healthy volunteers and assessing the effect of food on HCXT-2001. The second study is assessing single doses of “HCXT-2001 Tablets (A).” A third clinical trial, which is enrolling healthy adults in New Zealand, is testing “HCXT-2001 Tablets” and “HCXT-2001 Tablets (A).” HCXT-2001 is an oral macrocyclic peptide inhibitor of the IL-23 receptor. As J&J has shown with Icotyde, oral macrocyclic peptides can survive the gut to hit targets traditionally engaged by injectable medicines. However, food can affect the absorption of these drugs. Patients must wait (PDF) at least 30 minutes after taking Icotyde before eating. Merck & Co.’s Lipfendra has the same restriction. Targeting markets already served by Icotyde, PepStar extended the half-life of HCXT-2001. The first phase 1 trial could test daily and weekly administration of HCXT-2001 in its multiple-ascending-dose stage. Less frequent dosing and the potential to combine the peptide with emvistegrast “could represent key points of differentiation” for HCXT-2001, BMO analysts said. While HCXT-2001 is in early development, the asset could ultimately challenge drugs including Icotyde across a range of indications. IL-23 is implicated in an array of immune-mediated inflammatory diseases. Icotyde is approved for plaque psoriasis, while Skyrizi’s label covers plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.

Phase 1Drug ApprovalPhase 2License out/in

23 Oct 2026

·www.pharmaceutical-technology.com

Gilead spends $1.28bn on PepStar’s potential Icotyde rival

This deal from Gilead is the latest in a string the company has signed during 2026. Credit: hatsak / Shutterstock.com. Gilead Sciences has inked a billion-dollar deal with Shanghai-based PepStar therapeutics to secure the global rights to an oral IL-23 receptor inhibitor, which the company hopes will rival Johnson & Johnson’s recently approved therapy Icotyde (icotrokinra). Through this deal, Gilead will hand over $1.275bn upfront to obtain the rights to PepStar’s macrocyclic peptide IL-23R inhibitor pill programme. This includes its lead asset, HCXT-2001, which is currently in Phase I trials. While the IL-23R inhibitor class has thus far made its commercial mark in plaque psoriasis, clinical success is now being seen in inflammatory bowel disease (IBD). Gilead is prioritising the latter with HCXT-2001, though the company is yet to specify which specific indications it will pursue. Unlike other options on the market, HCXT-2001 has an extended half-life, leading Gilead’s CMO, Dietmar Berger to claim that the drug could offer a “potentially differentiated approach” to the company’s burgeoning inflammation pipeline – which is primarily focused on IBD, type 2 inflammatory diseases, lupus and B cell-mediated autoimmune diseases. “We see potential for HCXT-2001 alone or in combination, including with emvistegrast, as a daily oral treatment for people living with IBD,” Berger added. Emvistegrast is Gilead’s in-house developed α4β7 integrin inhibitor, which is currently in mid-stage development for IBD. The drug has already demonstrated its potential, having recently met its primary endpoint in patients with ulcerative colitis (UC) during the Phase II SWIFT study (NCT06290934). According to Jefferies analysts, this deal is a good move from Gilead as it allows the company to pursue a promising combination. “Proof of concept data from ABBV-266 [a combination of risankizumab and trosunilimab] shows that a4b7 + IL-23 may offer the best clinical remission in patients with prior advanced treatment,” they commented. Meanwhile, they add that preclinical pharmacokinetic studies have pointed toward the early favourability of HCXT-2001 versus Icotyde – pointing to early signs of the drug’s differentiated potential. Gilead doubles down on dealmaking Gilead’s deal with PepStar is the latest in a string of deals inked by the California-based pharma, which is currently preparing itself for several key patent expiries across its virology portfolio. To bolster its pipeline and bring new promising assets in, Gilead has inked three acquisitions in 2026. This includes its $7.8bn buyout of CAR-T specialist, Arcellx, as well as its takeovers worth up to $5bn and $2.2bn of antibody-drug conjugate (ADC) developer Tubulis and autoimmune T-cell engager (TCE) therapy-focused biotech Ouro Medicines, respectively. In the same vein, Gilead also recently forged a $1.9bn licensing pact with Vir Biotechnologies centred around next-generation TCEs for solid tumours. According to a recent report by GlobalData, parent company of Pharmaceutical Technology, more than half of the 157 surveyed pharmaceutical professionals feel optimistic or very optimistic about industry growth within the next 12 months.

Phase 1Phase 2License out/inAcquisitionADC

15 Oct 2026

·www.fiercebiotech.com

Chutes & Ladders—Bausch + Lomb's returning CEO Saunders exits again

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren Incorvaia, Marissa Russo or Donavyn Coffey, and it will be featured here at the end of each week. B+L’s Brent Saunders eyes the exit again Bausch + Lomb CEO Brent Saunders made a surprising second exit from the eye health company this week, less than four years into his latest tenure. Saunder’s exit was mutually agreed upon by the executive and the board of directors, Bausch + Lomb said in a statement. In his stead, Thomas Appio, CEO of parent company Bausch Health since 2022 and Bosch + Lomb chairperson as of August, will lead as interim CEO. “When I returned to Bausch + Lomb, I believed this company had tremendous potential,” said Saunders in a statement. “Today, it is stronger, more focused and better positioned for the future, with a clearer strategy, a more robust pipeline and significant opportunities ahead.” Evercore ISI analysts noted that the change in leadership is unexpected given the pipeline projections and commercial targets Bausch + Lomb had laid out. Appio’s interim takeover suggests the transition may have been a surprise to the company as well, the analyst speculated. Story Paragon imported Apogee's top brass after AbbVie buyout Four months after AbbVie announced its $10.9 billion deal to buy Apogee for its late-phase eczema drug zumilokibart, it appears Paragon has taken its pick of the biotech’s top talent. This includes Michael Henderson, M.D., who headed up Apogee until the sale and will now take up the same role at Paragon. Henderson will be joined at Paragon by several of his Apogee colleagues, namely head of R&D Carl Dambkowski, M.D., chief business and financial officer Dan Mulreany, chief legal officer Matt Batters and chief people officer Emily Cox. The Apogee alumni are no strangers to Paragon, as zumilokibart was originally developed at Paragon before the Boston-based biotech drug discovery hub spun out Apogee to take the anti-IL-13 antibody forward. Story RAS-focused Verastem unveils leadership transition Effective in the new year, Daniel Paterson will step down as CEO after a 15-year run at Verastem, with Michael Bailey set to take over as the cancer drugmaker's next helmsman. Paterson was involved in the acquisition of VS-7375 from GenFleet Therapeutics, as well as its rapid advancement to phase 2 clinical trials across multiple KRAS G12D-mutated tumor types. VS-7375 is an oral KRAS G12D dual ON/OFF inhibitor that just recently reported positive phase 1/2 data in multiple solid tumors, including metastatic pancreatic ductal adenocarcinoma. Bailey has served on Verastem’s board since May 2026, but prior to that had spent 16 years with Aveo Pharmaceuticals in multiple leadership positions, including chief business officer, chief commercial officer, and most recently CEO. Release > Bay area biotech Shenandoah Therapeutics shuffled its C-suite to advance its lead oncology program toward IND-enabling studies. eFFECTOR Therapeutics alum Steve Worland , Ph.D., was appointed CEO, while co-founder and founding CEO Isabella Graef , M.D., has transitioned to chief scientific officer. Release > Harmony Biosciences tapped board member and COO Peter Anastasiou as its new president and chief executive officer ahead of current captain Jeffrey Dayno , M.D.’s end-of-year retirement. Release > Matchpoint Therapeutics appointed Sanofi and CRISPR Therapeutics vet John O’Malley, M.D., Ph.D., as its new chief medical officer, as the company prepares to lead its lead covalent small molecule candidate into the clinic. Release > Massachusetts-based biotech Prologue Medicines brought on Stephen Harrison , Ph.D., as its new chief scientific officer to help scale the company’s Delve platform and advance its pipeline of viral protein-based medicines. Release > Shanghai AI-native biotech company Ailux tapped Llyod Miller , M.D., Ph.D., as its new chief medical officer. Miller previously served in leadership roles at Johnson & Johnson and led the strategy and clinical development of Icotyde, which was recently approved by the FDA. Release > Cardiometabolic biotech MetaVia appointed clinical development consultant Sarah Browne , M.D., as its next chief medical officer. Release > CRISPR gene editing biotech Intellia Therapeutics appointed Jing Marantz , M.D., Ph.D., as chief medical officer to help commercialize its first potential in vivo gene editing product and advance its phase 3 clinical trials in transthyretin amyloidosis. Release > Harry Welten is set to succeed Michael Salzmann , Ph.D., as CEO of AL-S Pharma following a phase 2 win for the company’s lead ALS candidate. The clinical-stage company plans to launch a phase 3 trial next year. Release > Italy's Sibylla Biotech, focused on leveraging the power of folding interference protein degradation to target proteins before they become undruggable, beefed up its C-suite as it aims to bring its lead program into clinical evaluation. Usman Azam , M.D., joined as Sibylla’s new CEO, with co-founder and previous CEO Lidia Pieri , Ph.D., moving to chief operating officer and Elena Ardini advancing from VP of R&D to chief scientific officer. Release > Nimbus Therapeutics bolstered its leadership with three new additions. Lizabeth Leveille joined from Merck Research Laboratories as Nimbus’ new chief business officer. Fang Wang , Ph.D., has joined as senior vice president and head of biology, and Daniel Price , Ph.D., was promoted to senior vice president and head of chemistry. Release

Executive ChangeAcquisitionDrug ApprovalPhase 3

100 Deals associated with Icotrokinra Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D13108	-	-	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Erythrodermic psoriasis	Japan	Janssen Pharmaceutical KK	16 Sep 2026
Pustular psoriasis	Japan	Janssen Pharmaceutical KK	16 Sep 2026
Plaque psoriasis	United States	Janssen Biotech, Inc.	17 Mar 2026

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Crohn Disease	NDA/BLA	Canada	Janssen, Inc.	01 Dec 2025
Immune System Diseases	Phase 3	China	-	15 Jan 2027
Immune System Diseases	Phase 3	Canada	-	15 Jan 2027
Immune System Diseases	Phase 3	Germany	-	15 Jan 2027
Immune System Diseases	Phase 3	Hungary	-	15 Jan 2027
Immune System Diseases	Phase 3	Poland	-	15 Jan 2027
Immune System Diseases	Phase 3	Spain	-	15 Jan 2027
Immune System Diseases	Phase 3	Turkey	-	15 Jan 2027
Colitis, Ulcerative	Phase 3	United States	Janssen Pharmaceutica NV	01 Oct 2025
Colitis, Ulcerative	Phase 3	United States	Janssen Research & Development LLC	01 Oct 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06220604 (ICONIC-ADVANCE 2 \| PSO-2, CTgov)	Phase 3	Plaque psoriasis	731	Placebo+JNJ-77242113 (Arm 1: Placebo Followed by JNJ-77242113 200 mg)	mlcsxpmyxh = cpxykhdisu otxmslvrxr (zsrfaqhxdi, fmmrmrynsr - fiyudirceb) View more	-	25 Jun 2026
				JNJ-77242113 (Arm 2: JNJ-77242113 200 mg)	mlcsxpmyxh = pgocqputax otxmslvrxr (zsrfaqhxdi, yqadueicxj - vszehvpvuf) View more
NCT06095102 (ICONIC-TOTAL \| PSO-4, CTgov)	Phase 3	Plaque psoriasis	311	placebo+JNJ-77242113 (Arm 1: Placebo)	ijahmlinix = nbyiuzswyr uztszfhtxd (bxjyddxxnb, jkvztewged - roqeidvklb) View more	-	25 Jun 2026
				JNJ-77242113 (Arm 2: JNJ-77242113 200 mg)	ijahmlinix = drbnjiqybl uztszfhtxd (bxjyddxxnb, ryitqcvnde - pnsqzoagmm) View more
NCT06143878 (ICONIC-ADVANCE 1 \| PSO-1, CTgov)	Phase 3	Plaque psoriasis	774	Placebo+JNJ-77242113 (Arm 1: Placebo Followed by JNJ-77242113 200 mg)	exvggutnon = uldztcbaqu evzvblztoh (wkxriakgln, wvfujpendn - mjxnosvlch) View more	-	25 Jun 2026
				JNJ-77242113 (Arm 2: JNJ-77242113 200 mg)	exvggutnon = ifrnqwjmyt evzvblztoh (wkxriakgln, cuacwstcig - ktbvsqlrlt) View more
ICONIC-LEAD (EULAR2026)	Phase 3	Plaque psoriasis	1,343	Icotrokinra 200 mg	bxwrbwcyhc(qmvsfjtani) = zedjxognhg ldmjjbjklq (jzbizmozgs ) View more	Positive	11 Jun 2026
				Placebo	bxwrbwcyhc(qmvsfjtani) = qmkpjvprhs ldmjjbjklq (jzbizmozgs ) View more
NCT06095115 (ICONIC-LEAD, EULAR2026)	Phase 3	Plaque psoriasis \| Arthritis, Psoriatic IL-23 receptor	216	Icotrokinra 200 mg	gzypeqrbhw(tmjfxbtlwu) = zhtpypzibq yixrnjhrrv (cefuelmtih ) View more	Positive	11 Jun 2026
				Placebo	gzypeqrbhw(tmjfxbtlwu) = qrcybastqh yixrnjhrrv (cefuelmtih ) View more
NCT06095115 (ICONIC-LEAD \| PSO-3, CTgov)	Phase 3	Plaque psoriasis	684	Placebo+JNJ-77242113 (Placebo to JNJ-77242113 200 mg)	muwkremxse = eecvyrdkhc ornnejmikl (kqhjnnacwp, enqtpxkccv - ornyfsaijv) View more	-	01 Jun 2026
				JNJ-77242113 (JNJ-77242113 200 mg)	muwkremxse = dibzilqgir ornnejmikl (kqhjnnacwp, qlsdermgxw - xeoezixovn) View more
NCT05364554 (FRONTIER 2, CTgov)	Phase 2	Plaque psoriasis	227	Placebo+JNJ-77242113 (Placebo Then JNJ-77242113 100 mg QD)	eujcjjvcww = cgoprzujgd vztxbblbrw (dhxwpsjihk, vtjiqkssmi - eccemblgqf) View more	-	01 Jun 2026
				JNJ-77242113 (JNJ-77242113 25 mg QD)	eujcjjvcww = tziavqugvw vztxbblbrw (dhxwpsjihk, ewpcykykal - slnjpkibzw) View more
NCT05357755 (SUMMIT, CTgov)	Phase 2	Plaque psoriasis	90	placebo+JNJ-77242113 (Placebo)	xngeioruca = ocvnqespoq ivbauznwpw (jxxspllkcy, qyzqxvhoah - mvywxpqfif) View more	-	05 May 2026
				JNJ-77242113 (JNJ-77242113 10 mg QD)	xngeioruca = oznnyqxkrk ivbauznwpw (jxxspllkcy, qpbqkppdvn - xfcllgjwaj) View more
NCT06095115 (ICONIC-LEAD, AAD2026)	Phase 3	Plaque psoriasis	1,343	Icotrokinra 200mg	eeixhnfzwv(xhllkgkonn) = gcvjjqeljp mxbcrfknrk (bndnthsysa ) View more	Positive	27 Mar 2026
				Placebo	eeixhnfzwv(xhllkgkonn) = fcljbliwud mxbcrfknrk (bndnthsysa ) View more
NCT06095115 (ICONIC-LEAD, AAD2026)	Phase 3	Plaque psoriasis	1,555	Icotrokinra 200mg	tmakzrvgkg(yaoxvzwzdt) = iaelrexvxc vdbrsunlcq (cjriyswsqj ) View more	Positive	27 Mar 2026
				Placebo	tmakzrvgkg(yaoxvzwzdt) = tlcectylvi vdbrsunlcq (cjriyswsqj ) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data